Antiviral proteins and peptides
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsMichael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
Life of this patent
Estimating the term…
Abstract
The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
Claims21
An isolated and purified antiviral protein or antiviral peptide from Nostoc ellipsosporum, wherein said protein or peptide comprises at least nine contiguous amino acids of SEQ ID NO:
- 2.
An isolated and purified antiviral protein or antiviral peptide, wherein said protein or peptide is encoded by an isolated and purified nucleic acid molecule encoding at least nine contiguous amino acids of SEQ ID NO:
- 2, wherein said at least nine contiguous amino acids of SEQ ID NO:
- 2 has antiviral activity.
An isolated and purified antiviral protein comprising the amino acid sequence of SEQ ID NO:
- 2 or a fragment thereof, wherein said fragment has antiviral activity.
An isolated and purified antiviral peptide comprising a fragment of the amino acid sequence of SEQ ID NO:
- 2, wherein said fragment has antiviral activity.
Dependencies are inferred from the claim text.